Epitherapeutics extends seed financing round, OSI Pharmaceuticals Inc. joins Syndicate

Copenhagen, Denmark - August 27, 2010

Epitherapeutics, a biopharmaceutical company making innovative pharmaceutical agents based on a leading scientific position in the field of epigenetics, announced today the participation of OSI Pharmaceuticals Inc. in an extension of its seed round, bringing the total seed financing to DKK 42 M since the inception of Epitherapeutics in October 2008. OSI Pharmaceuticals Inc. joins an investor group that includes LFI Life Science Investments, Novo Seeds and Seed Capital.

Click here to read Epitherapeutics' press release.